Mario Sznol, MD
The role of immunotherapy in metastatic renal cell carcinoma (mRCC) has grown tremendously with dual immune checkpoint inhibition and combinations of anti–PD-1/VEGF inhibitors, explained Mario Sznol, MD, in a presentation during the 13th Annual
Interdisciplinary Prostate Cancer Congress®
and Other Genitourinary Malignancies.
... to read the full story